WTA and Stats Perform Serve up Breakthrough Tennis AI and Data Partnership, in Landmark Deal for Women’s Sports
24.11.2020 16:00:00 EET | Business Wire | Press release
The WTA (Women’s Tennis Association) today named Stats Perform its Official WTA Data Supplier.
The transformative partnership will deliver multiple feeds to customers - an exclusive umpire-derived data feed for an expanded number of WTA matches, as well as an ultrafast data feed collected by Stats Perform’s Opta analysts.
The data collected by Stats Perform’s Opta analysts will include detailed match statistics down to rally and shot level. This will dramatically increase the level of live insight available for thousands of WTA matches to power a new range of broadcast, second screen, and betting experiences.
The data feed will support Stats Perform’s advanced AI capabilities which will be leveraged to help bring fans closer to the sport through engaging data-driven insights and stories. Through these unique insights, fans will be able to get to know the players and the game at a much deeper level.
The data also enhances Stats Perform’s existing live WTA video streaming service to help create the ultimate experience in trusted and entertaining in-play betting.
Stats Perform’s extensive sports content distribution capabilities will improve the availability of official WTA data to make it more accessible for authorized sportsbooks, broadcasters, OTT, media, sponsors, tech and fantasy games, giving fans and bettors fast, detailed and accurate tennis data.
As evidence of Stats Perform’s commitment to growing the profile of women athletes, the partnership will push more innovative insights and content to raise the profile of WTA players. The agreement also aims to elevate the betting experience through the delivery of faster, deeper feeds, and promote integrity in tennis via the provision of two operationally independent feeds.
Carl Mergele, CEO Stats Perform, says: “The WTA has very ambitious goals for their tournaments and players and we’re proud to be trusted to help them reach new levels of fan and bettor engagement. Our broadcaster, media, and betting networks are already excited because they’ve seen how high-quality information elevates sport’s appeal.”
Micky Lawler, WTA President, says: “Stats Perform has a history of creating innovative and trusted content and products that drive entertainment levels and new revenue streams for the professional sports ecosystem. We’re looking forward to discovering new and unique storylines surrounding the WTA Tour and our players and tournaments available in new, exciting and comprehensive ways.”
Atop its sports AI and content expertise and customer network, Stats Perform’s globally famous and trusted Opta data brand has helped it transform the way fans and bettors interact with men’s and women’s soccer, cricket, rugby, basketball, NFL and MLB. The company has a long history of challenging how sport is measured, giving players, teams and leagues a competitive edge and broadcasters, media, sportsbooks and sponsors new perspectives. Women’s tennis is now also set to see a rise in the profile of and engagement with the Tour and its players.
About Stats Perform
Stats Perform is the market leader in SportsTech providing the most trusted sports data and the latest advancements in applying AI and machine learning to deliver better predictions for teams, sportsbooks and a more engaging broadcast, media and fan experience. The company collects the most detailed sports data to create new experiences across sports. Leveraging the richest sports database, Stats Perform enhances sports competition and entertainment through machine learning and computer vision to create advanced predictions and analysis – be that for digital and broadcast media with differentiated storytelling, tech companies with reliable and fast data to power their innovations, sportsbooks with in-play betting and integrity services, or teams with first-of-its-kind AI analysis software. SportsContentCo is the exclusive reseller of Stats Perform premium sports betting content to licensed sportsbooks in the United States. For more information, visit StatsPerform.com or SportsContentCo.com.
About WTA
Founded by Billie Jean King in 1973 on the principle of equal opportunity for women in sports, the WTA is the global leader in women’s professional sport with more than 1,650 players representing 84 nations competing for a record $180 million in prize money. In 2019, the WTA was watched by a record-breaking global audience of 700 million. The 2020 WTA Tour includes 53 events and four Grand Slams, spanning across six continents and 28 countries and regions. The season culminates with the Shiseido WTA Finals Shenzhen, offering a $14 million total prize purse and honoring the season’s top singles and doubles players. Further information on the WTA can be found at www.wtatennis.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005368/en/
Contact information
Sarah Butler, Stats Perform PR Manager
Sarah.butler@statsperform.com / +44 07432631237
Amy Binder, WTA, abinder@wtatennis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom